Summary: Loss of smell and taste carries an emotional, social and psychological burden that can be as severe as many major chronic illnesses. A new narrative review examined years of clinical evidence and direct quality-of-life measurements across a wide range of long-term conditions to quantify that impact.
The review challenges the common misconception that olfactory and gustatory impairments are merely minor inconveniences. Instead, it documents consistently high rates of clinical depression, prolonged social isolation, nutritional disruption and persistent anxiety about personal safety among millions of people with smell and taste disorders.
Key Facts
- Chronic-illness equivalence: Standardized quality-of-life scores for people with smell and taste disorders (SATDs) often match or fall below scores reported for conditions such as diabetes, stroke, heart failure and Parkinson’s disease.
- Psychological impact: Patients frequently report emotional numbness, loss of pleasure in everyday activities and marked social withdrawal, accompanied by elevated rates of clinical depression and anxiety.
- Nutritional effects: The loss of flavor perception can turn eating into a functional chore, producing both dangerous weight loss for some and unhealthy weight gain for others as they seek intense flavours or sweetness to compensate.
- Safety concerns: Impaired chemosensation creates ongoing anxiety about environmental hazards—people with SATDs commonly feel unsafe because they cannot detect smoke, gas leaks or spoiled food.
- Gaps in care: Despite robust evidence of substantial harm, many health systems and frontline clinicians underestimate the seriousness of SATDs, resulting in limited diagnostic pathways, few specialist clinics and inadequate treatment options.
Source: University of East Anglia
UEA research finds smell loss can lower quality of life to levels seen in diabetes, stroke, Parkinson’s and kidney failure.
For most people, the ability to smell a morning coffee or taste a home-cooked meal goes unnoticed—until it is gone. The new review shows that when smell and taste disappear or become distorted, quality of life can decline sharply, leaving many patients with impairments comparable to serious, long-term health conditions.
The findings confront the widespread view that losing smell or taste is a minor inconvenience and reveal substantial, measurable harm that affects daily living, relationships and mental health.
How the research was conducted
Researchers carried out a narrative review of the literature, synthesizing years of data from multiple studies that compared standardized quality-of-life metrics—such as EQ-5D-5L and validated depression inventories—across a spectrum of chronic illnesses, including cardiovascular, respiratory and neurological conditions.
Prof. Carl Philpott of UEA’s Norwich Medical School, the study’s lead author, explains that the evidence consistently shows smell and taste disorders produce significant social, emotional and psychological suffering that can rival the burden of well-recognized long-term diseases. Patients reported losing pleasure in food, struggling with social activities and living with constant anxiety about safety when they cannot detect smoke, gas or spoiled food.
Prof. Philpott also highlighted the strikingly high and repeated rates of depression and social withdrawal seen among people with persistent chemosensory loss.
Food as fuel
Smell contributes the majority of what people experience as flavour. When olfactory input is lost or distorted, meals can taste bland, metallic or offensive. For some, this leads to poor appetite and significant weight loss; for others, it triggers overeating of highly flavoured, sugary or salty foods in an attempt to regain sensory satisfaction, resulting in weight gain and metabolic change.
The review emphasizes how sensory loss disrupts everyday rituals—family meals, celebrations and shared experiences—exacerbating isolation and diminishing life satisfaction.
Despite these profound consequences, many clinicians have historically dismissed persistent smell and taste disorders as minor or transient, and specialist services remain scarce.
Covid-19 highlighted the problem
The Covid-19 pandemic brought mass attention to anosmia (loss of smell) and ageusia (loss of taste) as many people experienced acute sensory changes. While many recovered, a significant number developed permanent or distorted perceptions—such as parosmia, where familiar smells become unpleasant.
According to the researchers, Covid exposed an existing, longstanding problem in which chemosensory conditions have been under-recognized and under-resourced by medicine. They call for improved recognition, investment in specialist clinics and expanded research into treatments to address substantial health and wellbeing needs.
The review, titled “Comparing Quality of Life in Smell and Taste Disorders With Other Chronic Conditions—A Narrative Review,” appears in the journal Clinical Otolaryngology and lists Natalia Glibbery, David Turner, Duncan Boak and Carl Philpott as authors.
Key Questions Answered:
A: The olfactory system connects directly to brain regions that regulate emotion and memory. Olfactory signals feed into the olfactory bulb and then to the amygdala and hippocampus, which underpin emotional responses and recollection. When this sensory pathway is disrupted, people can lose an important biological anchor for emotional memory and reward, producing a distinct form of emotional numbness and diminished emotional resilience.
A: Because smell makes up most of perceived flavour, its loss can turn eating into a bland or unpleasant task. Some patients avoid food and lose dangerous amounts of weight; others overcompensate by selecting highly processed, sweet or salty foods to elicit any sensory response, which can lead to rapid weight gain and related metabolic problems.
A: The review identifies systemic neglect: front-line clinicians often minimise or mislabel persistent sensory loss as temporary, diagnostic services are limited, specialist clinics are scarce and access to validated therapies is restricted. As a result, many patients face long-term, life-altering conditions with little professional support.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The full journal paper was reviewed.
- Additional explanatory context was added by editorial staff.
About this olfaction and depression research news
Author: Lisa Horton
Source: University of East Anglia
Contact: Lisa Horton – University of East Anglia
Image: The image is credited to Neuroscience News
Original Research: Open access. “Comparing Quality of Life in Smell and Taste Disorders With Other Chronic Conditions—A Narrative Review,” Natalia Glibbery, David Turner, Duncan Boak, Carl Philpott. Clinical Otolaryngology. DOI: 10.1111/coa.70119
Abstract
Comparing Quality of Life in Smell and Taste Disorders With Other Chronic Conditions—A Narrative Review
Objectives
Smell and taste disorders (SATDs) are increasingly common yet under-recognised. They affect physical health, social participation and psychological wellbeing. The authors previously reported cohort data using the Olfactory Disorder Questionnaire (ODQ), EQ-5D-5L and visual analogue scales, showing notable impacts on quality of life and mental health. This review aims to contextualize that burden by comparing SATD outcomes with other chronic conditions using established measures drawn from the literature.
Methods
A literature review covered studies from 1 January 2010 to 10 August 2024 to identify systematic reviews and papers reporting EQ-5D-5L or Beck Depression Inventory (BDI) values across chronic conditions, enabling direct comparison with SATD data.
Results
EQ-5D-5L and depression scores for patients with SATDs were comparable to those reported in a variety of chronic illnesses, including diabetes, stroke and several cardiovascular and respiratory disorders, indicating a serious and measurable disease burden.
Conclusion
The review highlights a substantial, often-overlooked burden from olfactory and gustatory dysfunction. Unlike many chronic conditions that have well-established treatment pathways, effective therapies for SATDs are limited. The authors call for more clinical recognition, research investment and development of specialist services to improve diagnosis, management and patient outcomes.
Key Points
- Smell and taste disorders are increasingly prevalent but often unrecognized.
- They substantially reduce quality of life across physical, social and psychological domains.
- Effective treatments remain limited and specialist services are sparse.
- Quality-of-life and depression measures in SATDs are comparable to many chronic conditions.
- More research and healthcare investment are needed to close the care gap for affected patients.
Conflicts of Interest
Carl Philpott is Associate Editor of the publishing journal and is a co-author of the review. The other authors report no conflicts of interest.